| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/18/2005 | US20050180957 composition comprising a fibrinogen, a fibrinolysis inhibitor, an angiogenic growth factor, one or more encapsulated cells, a thrombin and a divalent salt; stimulating vascularization at a transplant site |
| 08/18/2005 | US20050180956 SSAO enzyme substrates for vasorelaxation, and methods of use thereof |
| 08/18/2005 | US20050180952 agent has a higher tissue bioavailability in a particular tissue; benefits and improvements over conventional drug delivery methods including dose sparing, increased drug efficacy, reduced side effects, reduced metastatic potential and prolonged survival |
| 08/18/2005 | US20050180926 Inhalable aerosol medicament for the treatment or prevention of pain |
| 08/18/2005 | DE10360954B3 Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen Use of silibinin, its salts and / or its prodrugs together with α-lipoic acid for the treatment of chronic obstructive pulmonary disease |
| 08/18/2005 | DE102004002638A1 Kombinationen von Serotonin-Wiederaufnahme-Hemmern und Imidazolin-I2-Agonisten Combinations of serotonin reuptake inhibitors and imidazoline I2 agonists |
| 08/18/2005 | CA2555316A1 Combined pharmaceutical composition |
| 08/18/2005 | CA2555304A1 Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome |
| 08/18/2005 | CA2555199A1 Peptidylarginine deiminase 4 inhibitor |
| 08/18/2005 | CA2554975A1 Methods of preventing and treating sars using low ph respiratory tract compositions |
| 08/18/2005 | CA2554671A1 Chemokine ccr5 receptor modulators |
| 08/18/2005 | CA2554626A1 Silinane compounds as cysteine protease inhibitors |
| 08/18/2005 | CA2554262A1 Sustained-release preparations |
| 08/18/2005 | CA2553928A1 Susceptibility gene for myocardial infarction, stroke, and paod; methods of treatment |
| 08/18/2005 | CA2553886A1 Combined use of prame inhibitors and hdac inhibitors |
| 08/18/2005 | CA2553038A1 Compositions substantially free of galactomannan containing piperacillin and tazobactam |
| 08/18/2005 | CA2552937A1 Combination of (a) a dna topoisomerase inhibitor and (b) an iap inhibitor |
| 08/18/2005 | CA2552458A1 Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| 08/18/2005 | CA2551780A1 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
| 08/18/2005 | CA2550848A1 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 08/18/2005 | CA2549083A1 Anti-viral pharmaceutical compositions |
| 08/18/2005 | CA2548210A1 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods |
| 08/17/2005 | EP1564292A1 Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
| 08/17/2005 | EP1564210A1 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
| 08/17/2005 | EP1563858A1 Peritoneal dialysis method |
| 08/17/2005 | EP1563849A2 Methods and compositions for modulating the immune system and uses thereof |
| 08/17/2005 | EP1563848A1 New combinations of an anti-emetic agent and an enkephalinase inhibitor |
| 08/17/2005 | EP1563847A1 Agent eleveting dendritic cell precursor level in blood |
| 08/17/2005 | EP1563845A1 Remedies for allergic diseases |
| 08/17/2005 | EP1563839A1 A method of analgesia |
| 08/17/2005 | EP1563838A2 Irrigation solution and method for inhibition of pain and inflammation |
| 08/17/2005 | EP1562975A2 Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
| 08/17/2005 | EP1562903A2 Mucin synthesis inhibitors |
| 08/17/2005 | EP1562633A1 Pharmaceutical product for endonasal administration for treating central nervous system diseases and disorders |
| 08/17/2005 | EP1562615A1 Oral and dental composition |
| 08/17/2005 | EP1562612A1 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine |
| 08/17/2005 | EP1562602A2 Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness |
| 08/17/2005 | EP1562601A1 Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| 08/17/2005 | EP1562600A2 Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders |
| 08/17/2005 | EP1562597A2 Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| 08/17/2005 | EP1562587A2 Novel compositions and methods for the treatment of immune related diseases |
| 08/17/2005 | EP1562586A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 08/17/2005 | EP1562582A1 Cholesterol absorption inhibitors for the treatment of demyelination |
| 08/17/2005 | EP1562577A1 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents |
| 08/17/2005 | EP1562571A1 Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
| 08/17/2005 | EP1562564A2 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| 08/17/2005 | EP1562492A1 Method and apparatus for the detection and occlusion of blood vessels |
| 08/17/2005 | EP1436380B1 Composition comprising a lactobacillus strain and uses thereof |
| 08/17/2005 | EP1427830A4 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
| 08/17/2005 | EP1289951B1 Growth hormone secretagogues |
| 08/17/2005 | EP1253853A4 Method for classifying and treating physiologic brain imbalances using quantitative eeg |
| 08/17/2005 | EP1248651B1 Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension |
| 08/17/2005 | EP1225913B1 Use of nitric oxide for the treatment of airway constriction |
| 08/17/2005 | EP1185712B1 New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| 08/17/2005 | EP1109908B1 Methods for determining compounds for modulating the body weight |
| 08/17/2005 | EP1087775B1 Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| 08/17/2005 | EP1051500B1 Diagnosis and treatment of aur1 and/or aur2 related disorders |
| 08/17/2005 | EP1039891B1 Treatment of scar tissue using lipoic acid |
| 08/17/2005 | EP1023445B1 Cadherin derived growth factor and the application thereof |
| 08/17/2005 | EP1023067B9 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 08/17/2005 | EP1011710B1 Methods and compositions for optimization of oxygen transport by cell-free systems |
| 08/17/2005 | EP0939804B1 NEUTROKINE alpha |
| 08/17/2005 | EP0938305B1 Method of alleviating pain by means of combining tramadol with an nmda antagonist |
| 08/17/2005 | CN1656237A Antiviral inhibition of capsid proteins |
| 08/17/2005 | CN1656222A Antisense iap nucleobase oligomers and uses thereof |
| 08/17/2005 | CN1656114A Novel pancortin-pablo protein interactions and methods of use thereof |
| 08/17/2005 | CN1656066A Pharmaceutical combination |
| 08/17/2005 | CN1656058A Amide derivatives as inhibitors of the enzymatic activity of renin |
| 08/17/2005 | CN1655847A Self-administered contraceptive injection of oily solution |
| 08/17/2005 | CN1655846A Combination of a PDE inhibitor and a leukotriene receptor antagonist |
| 08/17/2005 | CN1655845A Use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases |
| 08/17/2005 | CN1655822A Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent |
| 08/17/2005 | CN1655821A Combination comprising a CDK inhibitor and doxorubicin |
| 08/17/2005 | CN1655820A Pharmaceutical combination of PDE5 inhibitors with ace inhibitors |
| 08/17/2005 | CN1655819A Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 08/17/2005 | CN1655818A Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
| 08/17/2005 | CN1655817A Oxygenating agents for enhancing host responses to microbial infections |
| 08/17/2005 | CN1655815A Process for the preparation and activation of substances and a means of producing same |
| 08/17/2005 | CN1655814A Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 08/17/2005 | CN1655813A Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 08/17/2005 | CN1655812A Anitmicrobial polymer conjugates |
| 08/17/2005 | CN1655811A 组合物及其治疗用途 The composition and therapeutic use |
| 08/17/2005 | CN1655809A Compositions and methods for treating and preventing necrosis |
| 08/17/2005 | CN1655806A Treatment of diseases involving defective gap junctional communication |
| 08/17/2005 | CN1655804A Method and composition for treating cardiovascular diseases by employing neuroregulation protein |
| 08/17/2005 | CN1655803A Methods of improving central nervous system functioning |
| 08/17/2005 | CN1655796A Treatment of post-menopausal complaints in breast cancer patients which comprises tibolone and a SERM |
| 08/17/2005 | CN1655792A Combination product of a 1, 4-benzothiepine 1, 1-dioxide compound with at least one other active ingredient and the use of the product |
| 08/17/2005 | CN1655787A Triple monoamine reuptake inhibitors for the treatment of chronic pain |
| 08/17/2005 | CN1655786A Combination of a DPP IV inhibitor and a cardiovascular compound |
| 08/17/2005 | CN1655784A Use of compounds that are effective as selective opiate receptor modulators |
| 08/17/2005 | CN1655779A Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
| 08/17/2005 | CN1655778A Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus |
| 08/17/2005 | CN1655775A Use of 20-HETE synthesizing enzyme inhibitors as therapy for cerebral vascular disease |
| 08/17/2005 | CN1655771A At least partially degradable films containing an active ingredient and method for the production thereof |
| 08/17/2005 | CN1655764A Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 08/17/2005 | CN1655763A Method for preparing polymer micelle pharmaceutical preparation containing drug for injection |
| 08/17/2005 | CN1655675A Combination therapy using trefoil peptides |
| 08/17/2005 | CN1654073A Paster for treating tinea unguium |
| 08/17/2005 | CN1214788C Compositions for treatment and prevention of cardiovascular diseases |